Matikas et al. have recently shown that breast cancer patients with CK-19(+) CTCs at baseline and at post-therapy had worse DFS and OS compared with patients with CK-19(−) CTCs at both time-points48. The gene discussed is KRT19; the disease is breast carcinoma.